RA CAPITAL MANAGEMENT, L.P.
Q2 2020 13F-HR Holdings
Net value change ($000)
+1,966,100
(62.1%)
New positions
18
Sold out positions
9
Turnover %
38.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Forma Therapeutics Holdings, Inc. | 418,952 | NEW |
| NVAX | 396,649 | NEW |
| PCVX | 173,513 | NEW |
| ASND | 173,449 | 31.3% |
| TGTX | 146,907 | 143.7% |
| MGNX | 128,003 | NEW |
| ChemoCentryx, Inc. | 109,912 | 65.5% |
| LEGN | 105,631 | NEW |
| ADAPY | 96,541 | 283.0% |
| ADVM | 91,844 | 129.3% |
Top Reduces (Value $000, Stocks/ETFs)
| Ra Pharmaceuticals, Inc. | -233,245 | -100.0% |
| EXEL | -77,920 | -100.0% |
| GILD | -40,968 | -100.0% |
| VSTM | -33,414 | -68.0% |
| ZOGENIX, INC. | -31,137 | -23.9% |
| ARVN | -24,829 | -16.8% |
| CGEN | -21,471 | -100.0% |
| ImmunoGen, Inc. | -17,617 | -100.0% |
| NVCR | -17,448 | -100.0% |
| 89bio, Inc. | -16,818 | -21.1% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|